137 related articles for article (PubMed ID: 36456172)
21. Mucinous phenotype and CD10 expression of primary adenocarcinoma of the small intestine.
Kumagai R; Kohashi K; Takahashi S; Yamamoto H; Hirahashi M; Taguchi K; Nishiyama K; Oda Y
World J Gastroenterol; 2015 Mar; 21(9):2700-10. PubMed ID: 25759539
[TBL] [Abstract][Full Text] [Related]
22. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
24. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
25. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous metastasis as a primary presentation of a pulmonary enteric adenocarcinoma.
Todisco A; Internò V; Stucci LS; Ostuni C; Lovero D; D'Oronzo S; Mele F; Duda L; Palmirotta R; Silvestris F
Int J Biol Markers; 2019 Dec; 34(4):421-426. PubMed ID: 31556336
[TBL] [Abstract][Full Text] [Related]
27. Primary Enteric Adenocarcinoma Lung with Mesenchymal Epithelial Transition Factor Amplification: A Case Report.
Shukla S; Pandey RK; Husain N; Srivastava A
Gulf J Oncolog; 2021 May; 1(36):76-78. PubMed ID: 35017140
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Surgical Outcomes Between Invasive Mucinous and Non-Mucinous Lung Adenocarcinoma.
Matsui T; Sakakura N; Koyama S; Nakanishi K; Sasaki E; Kato S; Hosoda W; Murakami Y; Kuroda H; Yatabe Y
Ann Thorac Surg; 2021 Oct; 112(4):1118-1126. PubMed ID: 33242433
[TBL] [Abstract][Full Text] [Related]
30. [Progress in pulmonary enteric adenocarcinoma].
Zuo Y; Bai H; Ying JM; Wang J
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):321-325. PubMed ID: 35448919
[TBL] [Abstract][Full Text] [Related]
31. MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis.
Dong Y; Zhou L; Zhao D; Li K; Liu Z; Che N; Liu H
Jpn J Clin Oncol; 2020 Jun; 50(6):701-711. PubMed ID: 32083303
[TBL] [Abstract][Full Text] [Related]
32. Diagnosis and treatment of primary pulmonary enteric adenocarcinoma: Report of Six cases.
Tu LF; Sheng LY; Zhou JY; Wang XF; Wang YH; Shen Q; Shen YH
World J Clin Cases; 2021 Oct; 9(30):9236-9243. PubMed ID: 34786410
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary enteric adenocarcinoma: an overview.
Palmirotta R; Lovero D; D'Oronzo S; Todisco A; Internò V; Mele F; Stucci LS; Silvestris F
Expert Rev Mol Med; 2020 Apr; 22():e1. PubMed ID: 32340641
[TBL] [Abstract][Full Text] [Related]
34. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
35. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.
Gow CH; Wu SG; Chang YL; Shih JY
Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807
[TBL] [Abstract][Full Text] [Related]
36. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.
Ritterhouse LL; Vivero M; Mino-Kenudson M; Sholl LM; Iafrate AJ; Nardi V; Dong F
Mod Pathol; 2017 Dec; 30(12):1720-1727. PubMed ID: 28776576
[TBL] [Abstract][Full Text] [Related]
37. [Clinicopathological features of SMARCA4-deficient lung adenocarcinoma: a study of 42 cases].
Han J; Gao XZ; Xu Y; Liu EJ; Du Q; Chen K; Li SL
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):136-142. PubMed ID: 38281780
[No Abstract] [Full Text] [Related]
38. A pulmonary enteric adenocarcinoma patient harboring a rare EGFR exon 19 P753S mutation: Case report and review.
Xu X; Chen D; Wu X; Wang Q
Front Oncol; 2022; 12():988625. PubMed ID: 36212391
[TBL] [Abstract][Full Text] [Related]
39. Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.
Sousa V; Rodrigues C; Silva M; Alarcão AM; Carvalho L
Rev Port Pneumol (2006); 2015; 21(3):113-25. PubMed ID: 25926253
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.
Zheng D; Wang R; Zhang Y; Pan Y; Cheng X; Cheng C; Zheng S; Li H; Gong R; Li Y; Shen X; Sun Y; Chen H
J Cancer Res Clin Oncol; 2016 Apr; 142(4):833-43. PubMed ID: 26646246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
